SciELO - Scientific Electronic Library Online

vol.2 issue4Central obesity and left ventricular hypertrophy regressionStatins in heart failure: "to give or not to give" author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Insuficiencia cardíaca

On-line version ISSN 1852-3862


LEMA, Luis R. Clinical experience with PDE-5 inhibitors. Insuf. card. [online]. 2007, vol.2, n.4, pp.163-167. ISSN 1852-3862.

Pulmonary hypertension is a serious disease of various origins. In the last ten years we have witnessed tremendous advancements in our understanding of the pathogenesis of pulmonary arterial hypertension. Several of these new insights have led to the development and clinical application of novel treatments for this devasting disease. Nitric oxide-a potent vasodilator- is a key player of pulmonary vasoregulation with cGMP as a second messenger. The effects of cGMP are limited by enzymatic degradation through phosphodiesterases (PDEs). Sildenafil a highly selective inhibitor of PDEs 5 improved pulmonary hemodynamics and exercise capacity for patients with pulmonary arterial hypertension as monotherapy and/or in combination with other vasodilators. This review article summarizes the pharmacology, clinical efficacy and safety of sildenafil and others PDEs5 inhibitors for the treatment of pulmonary arterial hypertension.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License